Neovii is focused on advancing research and development in critical medical fields, particularly solid organ transplantation, stem cell transplantation, and immune and hemato-oncological disorders. The company is dedicated to identifying and pursuing in-licensing and acquisition opportunities to enhance its product portfolio. Neovii aims to develop novel therapies that can significantly improve patient outcomes in areas where there are substantial unmet medical needs, particularly in transplantation and immune-related conditions.

In addition to its commitment to innovative therapies, Neovii actively engages in collaborative opportunities to further its research initiatives. The company emphasizes its interest in expanding its operations within the realms of transplantation, hemato-oncology, and immune disorders, showcasing its dedication to addressing complex health challenges through scientific advancement and strategic partnerships.

Switzerland

Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology.

Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in more than 40 countries world wide. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.

Neovii

Company Details